Overview

Granulocyte-Colony Stimulating Factor (G-CSF) as Optimizing Therapy for Pediatric Liver Transplantation

Status:
Enrolling by invitation

Trial end date:
2022-05-16

Target enrollment:

Participant gender:

Summary

This study compares the effect of human recombinant Granulocyte-Colony Stimulating Factor (G-CSF) in pediatric patients with liver cirrhosis with a control group. The study aims to observe improvement of (Pediatric End-stage Liver Disease) PELD score and nutritional status prior to liver transplantation procedure. In addition to the intervention, standard treatments for liver cirrhosis are also given for both groups. G-CSF is administered for 12 times. Condition of disease: Pediatric patient aged 3 months to 12 years old Liver cirrhosis Undernourished / Severe malnutrition PELD score 10-25 Intervention: Drug: Recombinant Human G-CSF Phase: Phase 3

Phase:

Phase 3

Details

Lead Sponsor:

Fakultas Kedokteran Universitas Indonesia

Collaborator:

Dr Cipto Mangunkusumo General Hospital

Treatments:

Lenograstim
Sargramostim